agree with your post. to add it's also contingent on FDA - BuBs is an announcement co - hyping up the temporary entry into the US but giving a2m the motivation to pursue a permanent market entry. a2 played its hand well - no supply to the IF scarce market unless there is a path to FDA approval. something must have worked behind the scenes and that is exactly what a2m is pursuing now. once that is in place they can make a measured entry into the market. if they get onto the US govt IF list - their number one customer could be the USA government!
A2M Price at posting:
$5.25 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)